Abstract
Breast cancer affects one in eight women in the United States, with a mortality rate that is second only to lung cancer. Although chemotherapy is widely used in breast cancer treatment, its side effects remain a challenge. One way to address this problem is through drug delivery by the internalization of cell-type-specific probes. Although nucleic acid aptamers are excellent probes for molecular recognition, only a few studies have demonstrated that aptamers can be internalized into living cells. Therefore, herein we report the development of a cancer-cell-specific DNA aptamer probe, KMF2-1a. By using the cell-SELEX method, this aptamer was selected against breast cancer cell line MCF-10AT1. Our results show that KMF2-1a is internalized efficiently and specifically to the endosome of target breast cancer cells. These results indicate that KMF2-1a is a promising agent for cell-type-specific intracellular delivery with both diagnostic and therapeutic implications.
Original language | English (US) |
---|---|
Pages (from-to) | 79-84 |
Number of pages | 6 |
Journal | ChemMedChem |
Volume | 7 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2 2012 |
Keywords
- Aptamers
- Breast cancer
- Drug delivery
- Internalization
- MCF-10AT1
ASJC Scopus subject areas
- Drug Discovery
- General Pharmacology, Toxicology and Pharmaceutics
- Molecular Medicine
- Biochemistry
- Pharmacology
- Organic Chemistry